Genmab AS (GMAB) Earnings Preview
The next report date is not scheduled yet. The facts below describe past reports and today's prices; none of them predicts the result.
- Move the option market prices in: no liquid straddle quote
- Typical move after a report: ±2.6% (median of the last 8, either direction)
- Model fair value (multi-method blend): $49.13 against a $53.63 price, a -8.4% model fair value differential
The last 8 reports
Reported EPS came in above the estimate 5 of 8 times.
| Reported | EPS estimate | EPS actual | Surprise | Stock move |
|---|---|---|---|---|
| Thu, Aug 6, 2026 | $0.37 | $0.54 | +45.9% | +1.9% |
| Thu, May 7, 2026 | $0.19 | $0.13 | -31.6% | -2.3% |
| Tue, Feb 17, 2026 | $0.37 | $0.21 | -43.2% | -2.8% |
| Thu, Nov 6, 2025 | $0.45 | $0.65 | +44.4% | -0.6% |
| Thu, Aug 7, 2025 | $0.39 | $0.54 | +38.5% | -5.5% |
| Thu, May 8, 2025 | $0.23 | $0.31 | +34.8% | -0.3% |
| Wed, Feb 12, 2025 | $0.28 | $0.84 | +200.0% | +6.3% |
| Wed, Nov 6, 2024 | $0.33 | $0.29 | -12.1% | +3.5% |